Friday, July 10, 2026

Patent intelligence · US

US 12049471

Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

granted A61PA61P35/00A61P37/00
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 18
Applicant portfolio 14
Patent details — US 12049471
Jurisdiction
US
Status
granted
Grant date
Jul 30, 2024
Expiration
Jul 25, 2044
Claims
16
CPC classes
A61P, A61P35/00, A61P37/00
View on Google Patents ↗

Quick answer

US 12049471 (Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof) is held by NURIX THERAPEUTICS, INC.. Status: granted. Granted Jul 30, 2024. Expires Jul 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61P, A61P35/00, A61P37/00

More from NURIX THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12377106

    Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK

    NURIX THERAPEUTICS, INC. · Expires Jul 31, 2045

    granted
  2. US 12234230

    Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

    NURIX THERAPEUTICS, INC. · Expires Feb 20, 2045

    granted
  3. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    NURIX THERAPEUTICS, INC. · Expires Oct 17, 2044

    granted
  4. US 12091426

    Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

    NURIX THERAPEUTICS, INC. · Expires Sep 12, 2044

    granted
  5. US 12016860

    Combination therapies with Cbl-b inhibitor compounds

    NURIX THERAPEUTICS, INC. · Expires Jun 20, 2044

    granted
  6. US 11951133

    3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

    NURIX THERAPEUTICS, INC. · Expires Apr 4, 2044

    granted
  7. US 11866442

    Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

    NURIX THERAPEUTICS, INC. · Expires Jan 4, 2044

    granted

Frequently asked questions

What is US patent 12049471?

US 12049471 (Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof) is held by NURIX THERAPEUTICS, INC.. Status: granted. Granted Jul 30, 2024. Expires Jul 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12049471?

NURIX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.

When does US 12049471 expire?

Our index shows an expiration date of Jul 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.